BostonGene develops biomedical software for advanced patient analysis and personalized therapy. Their platform utilizes artificial intelligence for molecular genetic and immune profiling, decoding cancer patients' molecular profiles, including the immune system and tumor microenvironment. This approach uncovers key disease drivers, identifies novel drug targets, and recommends effective treatments. By providing precise, clinically validated insights, BostonGene enables clinicians to drive precision medicine and advance oncology research.

Investors Include:

NEC (Japan), Japan Industrial Partners, Impact Investment Capital.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund